Background: Azithromycin has modest efficacy against malaria, and previous cluster randomized trials have suggested that mass azithromycin distribution for trachoma control may play a role in malaria control. We evaluated the effect of annual versus biannual mass azithromycin distribution over a 3-year period on malaria prevalence during the peak transmission season in a region with seasonal malaria transmission in Niger. Methods: Twenty-four communities in Matameye, Niger, were randomized to annual mass azithromycin distribution (3 distributions to the entire community during the peak transmission season) or biannual-targeted azithromycin distribution (6 distributions to children <12 years of age, including 3 in the peak transmission season and 3 in the low transmission season). Malaria indices were evaluated at 36 months during the high transmission season. Results: Parasitemia prevalence was 42.6% (95% confidence interval: 31.7%-53.6%) in the biannual distribution arm compared with 50.6% (95% confidence interval: 40.3%-60.8%) in the annual distribution arm (P = 0.29). There was no difference in parasite density or hemoglobin concentration in the 2 treatment arms. Conclusions: Additional rounds of mass azithromycin distribution during low transmission may not have a significant impact on malaria parasitemia measured during the peak transmission season.
S
tudies of mass azithromycin for trachoma control have suggested that azithromycin may play a role in malaria control. 1, 2 Azithromycin has activity against the apicoplast, an organelle that is required for plasmodium survival. [3] [4] [5] [6] Although it has been shown to be inferior to other antimalarial treatment options as first-line treatment, azithromycin is known to be safe for mass distribution, with millions of doses distributed annually as part of trachoma control programs. 7, 8 Mass azithromycin distribution for trachoma control has been shown to significantly decrease child mortality, an effect that may be partially mediated by reduction in infection burden. 9 Azithromycin has also been safely and effectively used as part of combination treatment strategies for the prevention of malaria in pregnant women. 10 Even though azithromycin monotherapy is not recommended for the treatment of malaria at the individual level, mass azithromycin distribution in malaria endemic regions could be beneficial if it reduces the malaria burden in communities.
Two previous substudies of a randomized controlled trial of mass azithromycin distribution for trachoma control in Niger found conflicting results comparing annual and biannual mass azithromycin for malaria. 1, 11 Compared with a single mass azithromycin distribution, 2 mass azithromycin distributions (6 months apart) were shown to lead to a significant reduction in malaria parasitemia. 1 However, there was no significant difference in malaria prevalence or parasitemia during the high transmission season between 3 annual compared with 6 biannual mass azithromycin distributions in a different set of communities. 11 Here, we report 36-month malaria parasitemia outcomes from the same trial collected during the peak transmission season after 3 annual or 6 biannual azithromycin distributions in the same communities in which a decrease in parasitemia prevalence was previously noted during the low transmission season after 2 mass azithromycin distributions compared with a single mass azithromycin distribution.
METHODS

Study Design
The Partnership for the Rapid Elimination of Trachoma (PRET) was a consortium of community randomized trials conducted in Niger, The Gambia and Tanzania (clinicaltrials.gov NCT00792922) comparing mass azithromycin distribution strategies for trachoma control. Complete methods for the PRET study have been reported previously. 12, 13 The present report focuses solely on the Niger trial, which enrolled participants in Matameye District, Zinder Region, between May 2010 and August 2013. Communities were randomized to one of 4 arms in a 2 × 2 factorial design: (1) annual treatment of all individuals in the community with a treatment coverage target of 80%; (2) annual treatment of all individuals in the community with a treatment coverage target of >90%; (3) biannual treatment of children 12 years of age and younger with a treatment coverage target of 80% or (4) Given low literacy rates in the study area, both institutional review boards approved verbal informed consent from local chiefs of each study community before randomization and verbal informed consent from the parent or guardian of each participant.
Study Setting
This study was conducted in Matemeye District, Zinder Region, Niger, which is situated in the Sahel of Sub-Saharan Africa and has a highly seasonal malaria epidemic. 14, 15 The region is holoendemic for malaria, and cases peak shortly after the peak rainfall, typically in September. 15 At the time of the study, the only programmatic activity ongoing in the region for malaria control was bednet distribution. There was no seasonal malaria chemoprevention program in this region at the time of the study. Individuals who self-referred for treatment to their local health post were treated or referred elsewhere for treatment.
Randomization
Communities were randomized by stratified block randomization within each CSI by high or low clinical trachoma prevalence in the community. Communities were categorized as high or low trachoma prevalence based on whether they were above or below the median trachoma prevalence in a given CSI. The random allocation sequence was generated by Travis C. Porco using the statistical package R (version 2.12; R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org).
Intervention
In the annual mass azithromycin distribution arm, all individuals 6 months of age and older in all communities were offered 1 mass azithromycin distribution per year. In the biannual mass azithromycin distribution arm, children 6 months to 12 years of age in all communities were offered 2 mass azithromycin distributions at approximately 6-month intervals: once during the low and once during the high transmission season. Enrolled children under 6 months of age in both groups and those allergic to macrolides were offered topical tetracycline ointment (1%) to be applied to both eyes (unobserved) twice a day for 6 weeks. Target antibiotic coverage in both arms was 80%, the WHO standard for trachoma control programs.
Clinical and Laboratory Assessments
Blood samples for determination of malaria prevalence were collected from a random sample of children in both arms at 36 months after baseline. Children were randomly selected from an annual census that was conducted before the annual treatment in each community. Blood samples were collected in September 2013 during the high transmission season for malaria. 15, 16 A target sample of 50 children randomly selected from each village was used for collection of blood samples for thick smear and hemoglobin assessment. In communities with fewer than 50 children, blood samples were collected from all children in the community. Thick blood smears were collected on glass slides, air dried, and stored at room temperature. Each thick blood smear was stained and examined by 2 microscopists masked to each other at Zinder Regional Hospital in Niger with 3% Giemsa who determined the presence or absence of Plasmodium parasites on the slides. Each microscopist independently counted the number of asexual parasites per 200 white blood cells to assess parasite density, and the median of these 2 parasite density readings was used in analysis. Hemoglobin concentration was determined using HemoCue AB (HemoCue, Ängelholm, Sweden).
Sample Size
The sample size for the trial was based on the primary trachoma outcome. 13 For the malaria outcome, the power calculation was based on malaria estimates from the low transmission season. 14 We estimated that a random sample of 50 children in 12 communities per arm (24 communities total) would provide 80% power to detect a 3% difference in malaria parasitemia, assuming a baseline prevalence of 10% and an intraclass correlation coefficient of 0.075.
Statistical Analysis
All analyses were conducted as intention to treat. To compare malaria prevalence between annual and biannual mass azithromycin distribution arms, an unadjusted mixed-effects logistic regression model was used with a fixed effect for study arm and a random effect for community to account for clustering within communities. Parasitemia and hemoglobin levels were compared using a linear mixed-effects regression model with a fixed effect for study arm and a random effect for community. As a sensitivity analysis, we repeated analyses using the community-level prevalence of malaria metrics, which does not require assumptions related to the structure of the covariance matrix. All P values were calculated with an exact permutation test accounting for the stratified randomization scheme. All analyses were conducted in R (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Of 1037 children from 24 communities with blood samples for malaria, 511 (49.3%) were in the annual mass azithromycin distribution arm and 526 (50.7%) were in the biannual mass azithromycin distribution arm (Fig. 1) . Baseline characteristics between children in communities randomized to annual and biannual distributions were well balanced (Table 1, Figure 2 ). Antibiotic coverage among children 6-60 months of age was 88.8% in the annual distribution arm and 80.8% in the biannual distribution arm (Table 2) . Antibiotic coverage was similar at each mass azithromycin distribution time point between the 2 study arms ( Table 2) .
Malariometric analyses are presented in Table 3 . Malaria prevalence in the biannual distribution arm was lower than in the annual distribution arm (42.6% vs. 50.6%), but this difference was not statistically significant in a model accounting for clustering (P = 0.29). The intracluster correlation coefficient for malaria parasitemia was 0.10 (95% confidence interval: 0.05-0.19). We did not detect a difference between study arms in mean parasite density (mean parasite density 6260 in the annual arm vs. 10,660 in the biannual arm, P = 0.57). Clinical malaria prevalence, defined as the presence of parasitemia plus fever, was similar in the biannual and annual arms (5.9% vs. 6.8%, P = 0.69). There was no difference in hemoglobin between the annual and biannual arms (9.2 g/dL in the annual compared with 9.5 g/ dL in the biannual arm, P = 0.21). Results were robust to analyses at both the community and individual levels ( Table 3) .
DISCUSSION
After 36 months of biannual mass azithromycin distribution, there was a nonsignificant decrease in malaria parasitemia relative to annual mass azithromycin distribution. In the same communities approximately 2 years before, malaria parasitemia prevalence during the low transmission season was significantly lower in communities that had received 2 mass azithromycin distributions compared with those that had received a single mass azithromycin distribution (19.5% compared with 29.8%). 1 These results are consistent with © 2017 Wolters Kluwer Health, Inc. All rights reserved.
mathematical models, which have suggested that mass drug administration for malaria may be maximally effective during the low transmission season. [17] [18] [19] It is possible that azithromycin is more effective at the community level for malaria control during the low transmission season because the probability of reinfection is lower after treatment. A previous study showed a short-term reduction (73%) in malaria parasitemia prevalence in communities with low (6% at baseline) prevalence after mass azithromycin distribution, but no long-term effect of azithromycin distribution at the community level. 20 A previous The results of this study are consistent with previously reported results from 24 different communities randomized to annual versus biannual mass azithromycin distribution over a 36-month period in the same study. 11 In these studies, samples were collected during the high transmission season. It is possible that multiple mass azithromycin distributions increase selection of azithromycin-resistant strains, although we were unable to assess this here. Previous studies have demonstrated mixed results for the effect of azithromycin treatment on the development of plasmodium resistance. 2, 23 Testing azithromycin resistance in plasmodium is challenging, and the degree to which resistance could mitigate the protective effects of azithromycin is unknown. As tests for azithromycin-resistant malaria become more readily available, it will be important to assess the role of azithromycin resistance in malaria in the context of mass drug administration.
The results of this analysis must be considered in the context of several limitations. In the annual distribution arm, all individuals in the community were eligible for treatment, whereas treatments were targeted to children 12 years of age and younger in the biannual arm. It is possible that treatment of additional individuals in the community outside of the targeted age range had an effect on malaria transmission. Thus, any effect of intervention cannot be attributed solely to treatment administration frequency. The WHO coverage target for trachoma control is 80%. Not every individual in every community was treated at each time point, and treatment coverage tended to be lower for older age groups. Blood samples for malaria testing were only collected at 12 and 36 months after randomization. We were unable to assess baseline malaria prevalence. In addition, baseline data on bed net coverage or use were not available. These data were collected in very different malaria transmission seasons, so we are unable to measure whether the burden of malaria was decreasing over time during ongoing mass azithromycin distribution. As expected, malaria parasitemia prevalence was higher in the present report than was noted in the same communities previously, likely due to different seasons of data collection. Given that all communities received either annual or biannual mass azithromycin distribution and there was no untreated comparison group, it may be difficult to detect modest differences in malaria parasitemia between communities treated with different frequencies over a 3-year period. Studies with a comparison group that did not receive azithromycin may be required to fully understand the effects of mass azithromycin distribution for malaria control. Larger studies may be necessary to detect the effect of azithromycin on malaria parasitemia. 
